{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:59:07Z","timestamp":1768568347880,"version":"3.49.0"},"posted":{"date-parts":[[2024,12,31]]},"group-title":"Obstetrics and Gynecology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,1,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide, which is often attributed to retained placenta (RP) after delivery. There are no biomarkers currently used to predict a risk of developing RP\/PPH prior to labor. The objective of this study was to determine relationships between placental biomarkers measured in the first and second trimesters and proxy measures of postpartum blood loss relative to preeclampsia status in the Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-Be (nuMoM2b) dataset. 2,192 participants had placental analytes drawn during the first and second trimesters (9-13 and 16-22 weeks gestation, respectively); the outcome was a composite of retained placenta and\/or PPH requiring blood transfusion (RP\/PPH). Using Kruskal-Wallis tests, median differences in levels of soluble fms-like tyrosine kinase-1 (sFlt-1), placental growth factor (PlGF), sFlt-1\/PlGF ratio, soluble endoglin (sEng), beta subunit of human chorionic gonadotropin (\u03b2-hCG), inhibin A (INHA), and pregnancy-associated protein-A (PAPP-A) were assessed between women with (n=67) and without (n=2125) RP\/PPH overall and stratified by preeclampsia status. Women with RP\/PPH had significantly higher median levels of sEng, \u03b2-hCG, INHA, PAPP-A in the second trimester and sFlt-1was higher in both first and second trimesters, which was observed again when stratifying by preeclampsia status. Our findings indicate that biomarkers associated with angiogenesis, particularly when measured in the second trimester, are important targets for further study of RP and\/or PPH pathophysiology and potential risk screening development.<\/jats:p>","DOI":"10.1101\/2024.12.30.24319779","type":"posted-content","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T18:20:13Z","timestamp":1735669213000},"source":"Crossref","is-referenced-by-count":0,"title":["Placental biomarkers in second trimester maternal serum are associated with postpartum hemorrhage: a secondary analysis of the NuMoM2b dataset"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6536-6888","authenticated-orcid":false,"given":"Julienne N.","family":"Rutherford","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K.","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6655-3500","authenticated-orcid":false,"given":"Elise N.","family":"Erickson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025010618350950000_2024.12.30.24319779v2.1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000002351"},{"key":"2025010618350950000_2024.12.30.24319779v2.2","unstructured":"WHO, A roadmap to combat postpartum haemorrhage between 2023 and 2030. 2023, Geneva: World Health Organization. 68."},{"issue":"3","key":"2025010618350950000_2024.12.30.24319779v2.3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijgo.2013.06.024","article-title":"New WHO recommendations on prevention and treatment of postpartum hemorrhage","volume":"123","year":"2013","journal-title":"Int J Gynaecol Obstet"},{"key":"2025010618350950000_2024.12.30.24319779v2.4","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(14)70227-X"},{"issue":"1","key":"2025010618350950000_2024.12.30.24319779v2.5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/AOG.0000000000004972","article-title":"Postpartum Hemorrhage Trends and Outcomes in the United States, 2000-2019","volume":"141","year":"2023","journal-title":"Obstetrics & Gynecology"},{"issue":"4","key":"2025010618350950000_2024.12.30.24319779v2.6","first-page":"247","article-title":"A national update on rates of postpartum haemorrhage and related interventions","volume":"18","year":"2020","journal-title":"Blood Transfus"},{"key":"2025010618350950000_2024.12.30.24319779v2.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1701-2163(16)34984-2"},{"issue":"11","key":"2025010618350950000_2024.12.30.24319779v2.8","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1701-2163(16)32308-8","article-title":"Postpartum hemorrhage","volume":"28","year":"2006","journal-title":"J Obstet Gynaecol Can"},{"issue":"6","key":"2025010618350950000_2024.12.30.24319779v2.9","first-page":"1025","article-title":"Preventing postpartum hemorrhage: managing the third stage of labor","volume":"73","year":"2006","journal-title":"Am Fam Physician"},{"key":"2025010618350950000_2024.12.30.24319779v2.10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-11-97"},{"key":"2025010618350950000_2024.12.30.24319779v2.11","doi-asserted-by":"publisher","DOI":"10.1097\/aog.0000000000003564"},{"issue":"6","key":"2025010618350950000_2024.12.30.24319779v2.12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/ajo.13599","article-title":"Predicting postpartum haemorrhage: a systematic review of prognostic models","volume":"62","year":"2022","journal-title":"Australia and New Zealand Journal of Obstetrics and Gynaecology"},{"key":"2025010618350950000_2024.12.30.24319779v2.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1548-1433.2011.01351.x"},{"issue":"3","key":"2025010618350950000_2024.12.30.24319779v2.14","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1099800418760997","article-title":"A Systematic Review of Placental Biomarkers Predicting Small-for-Gestational-Age Neonates","volume":"20","year":"2018","journal-title":"Biol Res Nurs"},{"key":"2025010618350950000_2024.12.30.24319779v2.15","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1161\/CIRCULATIONAHA.118.036632","article-title":"Placental Growth Factor as an Indicator of Maternal Cardiovascular Risk After Pregnancy","volume":"139","year":"2019","journal-title":"Circulation"},{"key":"2025010618350950000_2024.12.30.24319779v2.16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.mehy.2017.03.007","article-title":"Mild anemia during pregnancy upregulates placental vascularity development","volume":"102","year":"2017","journal-title":"Med Hypotheses"},{"issue":"2","key":"2025010618350950000_2024.12.30.24319779v2.17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3109\/14767058.2016.1168395","article-title":"Maternal hemoglobin concentration and hematocrit values may affect fetus development by influencing placental angiogenesis","volume":"30","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"2025010618350950000_2024.12.30.24319779v2.18","doi-asserted-by":"crossref","unstructured":"Cerdeira, A.S. and S.A. Karumanchi , Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med, 2012. 2(11).","DOI":"10.1101\/cshperspect.a006585"},{"key":"2025010618350950000_2024.12.30.24319779v2.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414838"},{"key":"2025010618350950000_2024.12.30.24319779v2.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2004.12.052"},{"key":"2025010618350950000_2024.12.30.24319779v2.21","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.preghy.2021.12.003","article-title":"Clinical interpretation and implementation of the sFlt-1\/PlGF ratio in the prediction, diagnosis and management of preeclampsia","volume":"27","year":"2022","journal-title":"Pregnancy Hypertension"},{"key":"2025010618350950000_2024.12.30.24319779v2.22","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317189"},{"issue":"2","key":"2025010618350950000_2024.12.30.24319779v2.23","first-page":"346","article-title":"New Gestational Phase\u2013Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1\/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia","volume":"63","year":"2013","journal-title":"Hypertension"},{"key":"2025010618350950000_2024.12.30.24319779v2.24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055352"},{"key":"2025010618350950000_2024.12.30.24319779v2.25","doi-asserted-by":"publisher","DOI":"10.1080\/00016340802253759"},{"issue":"3-4","key":"2025010618350950000_2024.12.30.24319779v2.26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10641955.2022.2066119","article-title":"Soluble endoglin versus sFlt-1\/PlGF ratio: detection of preeclampsia, HELLP syndrome, and FGR in a high-risk cohort","volume":"41","year":"2022","journal-title":"Hypertension in Pregnancy"},{"key":"2025010618350950000_2024.12.30.24319779v2.27","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2277"},{"issue":"1","key":"2025010618350950000_2024.12.30.24319779v2.28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.11622\/smedj.2017034","article-title":"Low maternal serum pregnancy-associated plasma protein-A as a risk factor of preeclampsia","volume":"59","year":"2018","journal-title":"Singapore Medical Journal"},{"issue":"9","key":"2025010618350950000_2024.12.30.24319779v2.29","first-page":"e018219","article-title":"PAPPLA2 and Inhibin A as Novel Predictors for Pregnancy Complications in Women With Suspected or Confirmed Preeclampsia","volume":"29","year":"2020","journal-title":"Journal of the American Heart Association"},{"issue":"4","key":"2025010618350950000_2024.12.30.24319779v2.30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1159\/000322742","article-title":"Early detection of preeclampsia using inhibin a and other second-trimester serum markers","volume":"29","year":"2011","journal-title":"Fetal Diagnosis and Therapy"},{"key":"2025010618350950000_2024.12.30.24319779v2.31","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.placenta.2007.02.002","article-title":"HCG in the regulation of placental angiogenesis. Results of an in vitro study","volume":"28","year":"2007","journal-title":"Placenta"},{"issue":"3","key":"2025010618350950000_2024.12.30.24319779v2.32","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/01443615.2017.1340441","article-title":"The association between maternal serum first trimester free \u03b2hCG, second trimester intact hCG levels and foetal growth restriction and preeclampsia","volume":"38","year":"2018","journal-title":"Journal of Obstetrics and Gynaecology"},{"key":"2025010618350950000_2024.12.30.24319779v2.33","doi-asserted-by":"crossref","first-page":"619530","DOI":"10.3389\/fendo.2021.619530","article-title":"Predictive Performance of Serum \u03b2-hCG MoM Levels for Preeclampsia Screening: A Meta-Analysis","volume":"12","year":"2021","journal-title":"Frontiers in Endocrinology"},{"key":"2025010618350950000_2024.12.30.24319779v2.34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.preghy.2023.11.003","article-title":"Association between human chorionic gonadotropin (hCG) levels and adverse pregnancy outcomes: A systematic review and meta-analysis","volume":"34","year":"2023","journal-title":"Pregnancy Hypertension"},{"key":"2025010618350950000_2024.12.30.24319779v2.35","unstructured":"Abrams, E. and J. Rutherford , Is postpartum hemorrhage a legacy of our evolutionary past?, in A Textbook of Postpartum Hemorrhage, L. Keith and C. Jones , Editors. 2012, Sapiens: London. p. 55\u201363."},{"key":"2025010618350950000_2024.12.30.24319779v2.36","doi-asserted-by":"crossref","first-page":"e12702","DOI":"10.1111\/aji.12702","article-title":"Elevated maternal placental protein 13 serum levels at term of pregnancy in postpartum major hemorrhage (>1000 mLs). A prospective cohort study","volume":"78","year":"2017","journal-title":"American Journal of Reproductive Immunology"},{"key":"2025010618350950000_2024.12.30.24319779v2.37","doi-asserted-by":"publisher","DOI":"10.1016\/J.AJOG.2015.01.019"},{"key":"2025010618350950000_2024.12.30.24319779v2.38","unstructured":"Silver, R. , Nulliparous Pregnancy Outcomes Study: Monitoring Mothers-to-be [dataset], N.D.a.S. Hub , Editor. 2019."},{"issue":"10","key":"2025010618350950000_2024.12.30.24319779v2.39","first-page":"1081","article-title":"Levels of angiogenic factors in pregnancy and post-partum bleeding","volume":"87","year":"2010","journal-title":"Acta Obstetrica et Gynecologica Scandinavica"},{"issue":"2","key":"2025010618350950000_2024.12.30.24319779v2.40","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.preghy.2011.11.006","article-title":"Association between placental growth factor levels in early onset preeclampsia with the occurrence of postpartum hemorrhage: A prospective cohort study","volume":"2","year":"2012","journal-title":"Pregnancy Hypertens"},{"issue":"8","key":"2025010618350950000_2024.12.30.24319779v2.41","first-page":"6026","article-title":"Correlation analysis of AFP and \u03b2-hCG on obstetric complications and pregnancy outcomes","volume":"13","year":"2020","journal-title":"International Journal of Clinical and Experimental Medicins"},{"key":"2025010618350950000_2024.12.30.24319779v2.42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s12905-024-03105-z","article-title":"Relationship between increased maternal serum free human chorionic gonadotropin levels in the second trimester and adverse pregnancy outcomes: a retrospective cohort study","volume":"24","year":"2024","journal-title":"BMC Womens Health"},{"key":"2025010618350950000_2024.12.30.24319779v2.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(99)70448-5"},{"key":"2025010618350950000_2024.12.30.24319779v2.44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12884-019-2266-y","article-title":"A cohort study of the association between maternal serum Inhibin-A and adverse pregnancy outcomes: a population-based study","volume":"19","year":"2019","journal-title":"BMC Pregnancy Childbirth"},{"issue":"20","key":"2025010618350950000_2024.12.30.24319779v2.45","first-page":"9955","article-title":"Elevated first-trimester PAPP-A is a marker in high-risk pregnancies with an increased risk of placenta accreta in predicting adverse outcomes","volume":"27","year":"2023","journal-title":"European Review for Medical and Pharmacological Sciences"},{"issue":"19","key":"2025010618350950000_2024.12.30.24319779v2.46","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.3390\/jcm12196175","article-title":"Red Blood Cell Transfusion after Postpartum Hemorrhage: Clinical Variables Associated with Lack of Postpartum Hemorrhage Etiology Identification","volume":"12","year":"2023","journal-title":"Journal of Clinical Medicine"},{"key":"2025010618350950000_2024.12.30.24319779v2.47","unstructured":"WHO, WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012."},{"key":"2025010618350950000_2024.12.30.24319779v2.48","first-page":"230","article-title":"Duration of third stage labour and postpartum blood loss: a secondary analysis of the WHO CHAMPION trial data","volume":"2021","year":"2021","journal-title":"Reproductive Health"},{"key":"2025010618350950000_2024.12.30.24319779v2.49","doi-asserted-by":"crossref","unstructured":"Frolova, A. , et al., Duration of the Third Stage of Labor and Risk of Postpartum Hemorrhage. Obstetrics & Gynecology, 2016. 127(951-956).","DOI":"10.1097\/AOG.0000000000001399"},{"issue":"8","key":"2025010618350950000_2024.12.30.24319779v2.50","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/01.ogx.0000271137.81361.93","article-title":"Systematic Review of Conservative Management of Postpartum Hemorrhage: What to Do When Medical Treatment Fails","volume":"62","year":"2007","journal-title":"Obstetrical & Gynecological Survey"},{"key":"2025010618350950000_2024.12.30.24319779v2.51","first-page":"1594","article-title":"Pre-eclampsia: FDA approves blood test to identify pregnant women at risk","volume":"382","year":"2023","journal-title":"British Journal of Medicine"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2024.12.30.24319779","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:24:12Z","timestamp":1768508652000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2024.12.30.24319779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2024.12.30.24319779","relation":{},"subject":[],"published":{"date-parts":[[2024,12,31]]},"subtype":"preprint"}}